Anti-SARS-CoV-2 S2 Protein Polyclonal Antibody

Catalog No.

PVV00501

Species reactivity

SARS-CoV-2 (2019-nCoV)

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant SARS-CoV-2 S2 Protein (Ser686-Pro1213).

Tested applications

ELISA: 1:4000-1:8000, WB: 1:2000-1:8000

Target

S2 Protein,Spike protein S2,Spike protein S2',Spike glycoprotein,S glycoprotein,E2,Peplomer protein,Spike protein S1,S

Purification

Purified by antigen affinity column.

Accession

P0DTC2

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET., PMID:40461447

Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603

Allostery Links hACE2 Binding, Pan-variant Neutralization and Helical Extension in the SARS-CoV-2 Spike Protein., PMID:40447075

mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 variant in the lower and upper respiratory tract., PMID:40342969

Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry., PMID:40285013

Self-assembled epitope-based nanoparticles targeting the SARS-CoV-2 spike protein enhanced the immune response and induced potential broad neutralizing activity., PMID:40270771

Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses., PMID:40226608

Structural basis and mode of action for two broadly neutralizing nanobodies targeting the highly conserved spike stem-helix of sarbecoviruses including SARS-CoV-2 and its variants., PMID:40215243

Capture of fusion-intermediate conformations of SARS-CoV-2 spike requires receptor binding and cleavage at either the S1/S2 or S2' site., PMID:40198676

Membrane-targeted immunogenic compositions using exosome mimetic approach for vaccine development against SARS-CoV-2 and other pathogens., PMID:40157987

Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma., PMID:40133428

Determinants and dynamics of the seroprevalence of anti-SARS-CoV-2 antibodies in Poland., PMID:40097104

Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine., PMID:40088511

Unveiling the Complete Spectrum of SARS-CoV-2 Fusion Stages by In Situ Cryo-ET., PMID:40060467

A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants., PMID:40000611

NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants., PMID:39994733

Transmembrane protease serine 2 (TMPRSS2) inhibitors screened from an Fv-antibody library for preventing SARS-CoV-2 infection., PMID:39990164

High rate of RNAemia and impaired immunity in patients with immunodeficiency in the vaccination era., PMID:39985863

Concordance of maternal and cord blood SARS-COV-2 immunoglobulin seropositivity after COVID-19 infection or vaccination in pregnancy., PMID:39973524

Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold., PMID:39966941

A shark-derived broadly neutralizing nanobody targeting a highly conserved epitope on the S2 domain of sarbecoviruses., PMID:39955548

Recombinant protein HR212 targeting heptad repeat 2 domain in spike protein S2 subunit elicits broad-spectrum neutralizing antibodies against SARS-CoV-2 and its variants., PMID:39931737

A novel method for detecting SARS-CoV-2 IgM and IgG based on the gold immune chromatography assay., PMID:39929938

Structural prediction of chimeric immunogen candidates to elicit targeted antibodies against betacoronaviruses., PMID:39908344

Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques., PMID:39847599

Reverse mutational scanning of SARS-CoV-2 spike BA.2.86 identifies epitopes contributing to immune escape from polyclonal sera., PMID:39827186

Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice., PMID:39774966

Characterization of Site-Specific N- and O-Glycopeptides from Recombinant Spike and ACE2 Glycoproteins Using LC-MS/MS Analysis., PMID:39769415

Structural Immunology of SARS-CoV-2., PMID:39731211

Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults., PMID:39723823

Cross-neutralization of distant coronaviruses correlates with Spike S2-specific antibodies from immunocompetent and immunocompromised vaccinated SARS-CoV-2-infected patients., PMID:39678346

SARS-CoV-2 Omicron variations reveal mechanisms controlling cell entry dynamics and antibody neutralization., PMID:39621785

Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo., PMID:39621673

Display of Native SARS-CoV-2 Spike on Mammalian Cells to Measure Antibody Affinity and ADCC., PMID:39600972

Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV., PMID:39589795

A statistically established reference value determined for the Vaxarray Coronavirus (CoV) seroassay to characterize vaccination and natural infection., PMID:39548371

Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection., PMID:39516286

Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens., PMID:39337303

Discovery and characterization of a pan-betacoronavirus S2-binding antibody., PMID:39326419

Preventing SARS-CoV-2 infection using Fv-antibodies targeting the proprotein convertase (PPC) cleavage site., PMID:39290379

Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection., PMID:39248629

A nonadjuvanted HLA-restricted peptide vaccine induced both T and B cell immunity against SARS-CoV-2 spike protein., PMID:39242614

Characterization of monoclonal antibodies targeting SARS-CoV-2 spike glycoprotein: Reactivity against Delta and Omicron BA.1 variants., PMID:39216601

Formulation Development of a COVID-19 Recombinant Spike Protein-Based Vaccine., PMID:39203956

Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens., PMID:39191724

Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters., PMID:39162540

XBB.1.16-RBD-based trimeric protein vaccine can effectively inhibit XBB.1.16-included XBB subvariant infection., PMID:39156763

Structure and inhibition of SARS-CoV-2 spike refolding in membranes., PMID:39146425

Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein., PMID:39125749

Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients., PMID:39122634

Document Download

Anti-SARS-CoV-2 S2 Protein Polyclonal Antibody.pdf